10x Genomics Reports First Quarter 2021 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/11/2026
- Wall St futures muted as US-Iran impasse lifts oil prices
- S&P 500 EPS growth above 20% is rare. Why 2027 may be at risk
- Goldman Sachs warns AI investment may be crowding out other business spending
- On Holding shares fall sharply after Q2 sales miss
- Citi bullish on MongoDB stock, expects 'significant positive estimate revisions'
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
- After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR
10x Genomics (TXG) Tops Q1 EPS by 16c, Revenues Beat; Offers FY21 Revenues Mid-Point Guidance Below Consensus
May 5, 2021 4:36 PM EDT10x Genomics (NASDAQ: TXG) reported Q1 EPS of ($0.11), $0.16 better than the analyst estimate of ($0.27). Revenue for the quarter came in at $105.8 million versus the consensus estimate of $102.51 million.
Recent Highlights
Revenue was $105.8 million for the first quarter, representing a 47% increase over the corresponding period of... More